NCT01959230View on ClinicalTrials.gov

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 7, 2013

Primary Completion Date

December 20, 2013

Study Completion Date

December 20, 2013

Conditions
Hyperemia
Interventions
DRUG

Brimonidine Tartrate

Ophthalmic solution to be applied as directed.

DRUG

Vehicle

Ophthalmic solution to be applied as directed.

DRUG

Sodium Fluorescein

For use as needed during the study for evaluating corneal damage.

DRUG

Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

Trial Locations (1)

38119

Bausch & Lomb Incorporated, Memphis

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01959230 - Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness | Biotech Hunter | Biotech Hunter